Madrid

• Atacicept in Multiple Glomerular Diseases Recruiting
  2024-518465-10-00 4 2025-12-12 Multiple Autoimmune Glomerular Diseases
• A study to investigate the safety and efficacy of ONA-255 in participants with advanced cancer Recruiting
  2025-522233-62-00 7 2025-12-12 Advanced cancer; breast cancer; metastatic gastric / gastroesophageal
• Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Recruiting
  2024-513619-28-00 1 2025-12-11 Clear Cell Renal Cell Carcinoma
• EPIK-P4: A Phase II single-arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patien … Recruiting
  2024-519960-42-00 4 2025-12-11 PIK3CA-Related Overgrowth Spectrum (PROS)
• PHASE 2B TRIAL OF AEF0217 IN PARTICIPANTS WITH DOWN SYNDROME Recruiting
  2025-521013-10-00 4 2025-12-11 Treatment of behavioural and cognitive impairments in Down syndrome.
• A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting
  2024-512904-21-00 4 2025-12-10 Migraine
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting
  2024-517980-22-00 4 2025-12-10 Multiple Sclerosis (MS)
• Brimonidine eye drops in the prevention of myopia progression Recruiting
  2025-521878-33-00 4 2025-12-10 Myopia
• Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re … Recruiting
  2024-515201-26-00 4 2025-12-09 Small cell lung cancer (SCLC)
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat … Recruiting
  2024-519913-76-00 4 2025-12-09 PDL1-negative metastatic triple-negative breast cancer
• A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascula … Recruiting
  2025-521349-25-00 5 2025-12-09 Macular neovascularization secondary to age-related macular degenerati
• A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non … Recruiting
  2024-515125-28-00 4 2025-12-08 Non-obstructive hypertrophic cardiomyopathy
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting
  2024-519712-13-00 5 2025-12-08 Hypertriglyceridemia (HTG)
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous … Recruiting
  2025-520730-28-00 4 2025-12-08 Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting
  2024-517261-16-00 9 2025-12-05 Advanced solid tumors
• A Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Na … Recruiting
  2024-517711-70-01 4 2025-12-04 Narcolepsy without Cataplexy (NT2)
• A Phase 3 study of Omaveloxolone in participants with Friedreich’s Ataxia Ages 2 < 16 years Recruiting
  2025-520896-13-00 5 2025-12-04 Friedreich’s ataxia
• Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Recruiting
  2025-521278-32-00 4 2025-12-04 Idiopathic Pulmonary Fibrosis (IPF)
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• A 52-week study of rilzabrutinib efficacy and safety compared to placebo in adults diagnosed with IgG4-related disease Recruiting
  2025-521398-15-00 5 2025-12-04 Immune system diseases

Showing 817–840 of 3,550 trials